Drug Companies Tie Costs to Outcomes

Drug Companies Tie Costs to Outcomes
By Peter Loftus

Sept. 12, 2017 10:07 p.m. ET

But early signs show little evidence that the plans lower prices
In one deal, Gilead Sciences Inc. agreed to pay Cigna additional rebates if its hepatitis C drug Harvoni cured less than 95% of Cigna’s patients who took it, he says. Cure rates have exceeded that threshold and Gilead hasn’t paid additional rebates beyond a base rebate that isn’t tied to the drug’s performance.

Continue reading....